Clinical trial register · Japan

Clinical Trials in Chiba, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC

2493

Studies in scope

all four open statuses

1263

Recruiting now

open to new participants

349

Lead sponsors

across recruiting studies

Top sites

Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348

Trials with a site in Chiba

Status

Study

Lead sponsor

Phase

Enrol

Sites in Japan

Start

Recruiting

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

NCT07794761Obesity

DrugBerobenatide

Pfizer

Phase 3

180

Chiba, Matsuyama, Fukuoka, Kasuya-gun, Sapporo, Amagasaki, Mito, Naka

2026-10-02

Recruiting

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer

DrugsTorvutatug samrotecan·Bevacizumab

AstraZeneca

Phase 3

600

Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe

2026-09-24

Recruiting

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugsSaruparib·Abiraterone·Darolutamide·Enzalutamide

AstraZeneca

Phase 3

1,330

Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe

2026-09-15

Recruiting

A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

NCT07734116Pediatric Malignant Solid Tumor and Epithelioid Sarcoma

DrugONO-4538HSC

Ono Pharmaceutical Co., Ltd.

Phase 1/2

Chiba, Kashiwa, Fukuoka, Hiroshima, Sapporo, Kanazawa, Yokohama, Kyoto

2026-09-15

Recruiting

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

NCT07743580SARS-CoV-2

DrugSecutrelvir

Shionogi

Phase 3

2,000

Kasugai-Shi, Chiba, Nihommatsu, Fujioka-Shi, Koyagimachi, Maebashi, Takasaki-shi, Akashi-Shi

2026-09-14

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Chiba, Toon-shi, Kobe, Hitachi, Tsu, Miyazaki, Bunkyo-Ku, Chuo-shi

2026-09-10

Recruiting

AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight

NCT07822061Overweight, Obesity

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

Sapporo, Yamato-shi, Chigasaki-shi, Kawasaki-shi, Suita-shi, Aichi, Bunkyo-ku, Tokyo, Chiba

2026-09-07

Recruiting

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305Renal Insufficiency, Chronic

DrugDapagliflozin

AstraZeneca

Phase 3

2,800

Ageo, Asahi-shi, Chiba, Fukaya, Fukui-shi, Izumisano, Izunokuni-shi, Kariya

2026-09-01

Not yet open

Breakthrough Platform Trial for PCAS

NCT07769086Cardiac Arrest (CA), Post Cardiac Arrest Syndrome

Kagawa University

Not applicable

630

Chiba, Iizuka, Hiroshima, Kobe, Kita-gun, Kyoto, Sendai, Okayama

2026-09-01

Recruiting

A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

NCT07766018Breast Cancer

DrugElacestrant

Stemline Therapeutics, Inc.

Phase 2

Chiba, Fukuoka, Ina, Isehara, Kōtō City, Kumamoto, Nagoya, Osaka

2026-08-18

Recruiting

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy

DrugAtrasentan

Novartis Pharmaceuticals

Phase 3

Nagoya, Kanazawa, Chiba, Fukuoka

2026-08-06

By invitation

Effect of Surgical Masks in Preventing Acute Respiratory Infections

NCT07739446Acute Respiratory Infections (ARIs), Influenza, COVID - 19

Chiba University

Not applicable

2,400

Chiba

2026-07-31

Recruiting

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Chiba, Narashino, Yahatanishi-ku, Kita Kyushu-shi, Sapporo, Kobe, Okayama, Minato-ku, Mitaka-shi

2026-07-21

Recruiting

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

NCT07699939Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsSerplulimab·Oxaliplatin

National Cancer Center, Japan

Phase 2

136

Chiba, Fukuoka, Gifu, Maebashi, Hiroshima, Kawasaki, Yokohama, Ina

2026-07-15

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

800

Amagasaki-shi, Chiba, Chitose-shi, Chūōku, Koga-shi, Minatoku, Okayama, Oyama-shi

2026-07-06

Active, closed

A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women

NCT07596199Diphtheria-Tetanus-acellular Pertussis Vaccines

DrugBoostrix

GlaxoSmithKline

Phase 3

102

Aichi, Chiba, Fukui, Fukuoka, Fukushima, Hokkaido, Kanagawa, Kyoto

2026-06-29

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo

2026-05-31

Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular

Eli Lilly and Company

Phase 1

215

Chiba, Okayama, Tokyo

2026-05-28

Recruiting

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 3

350

Chiba, Hiroshima, Itabashi-ku, Yokohama, Ōmura, Kashihara, Niigata, Suita

2026-05-14

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe

2026-05-04

Recruiting

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

NCT07623616Acute Myeloid Leukemia (AML)

DrugZiftomenib

Kyowa Kirin Co., Ltd.

Phase 2

Chiba, Gifu, Hyōgo, Ibaraki, Kagoshima, Kanagawa, Kyoto, Miyagi

2026-04-23

Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma

DrugRituximab

Eli Lilly and Company

Phase 1

460

Chiba, Okayama, Tokyo

2026-04-17

Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311Multiple Myeloma

DrugsBelantamab mafodotin·Velcade·Carfilzomib·Pomalidomide

GlaxoSmithKline

Phase 2

200

Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Ishikawa, Numakunai

2026-04-15

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

Nagoya, Chiba, Kashiwa, Matsuyama, Yokohama, Kurashiki, Osaka, Suita

2026-03-13

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)

DrugEnpatoran

EMD Serono Research & Development Institute, Inc.

Phase 3

202

Nagoya, Chiba, Kitakyushu-shi, Fukushima, Asahikawa-shi, Sapporo, Kobe, Kanazawa

2026-03-10

Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsCetuximab·Nab-paclitaxel·Gemcitabine

Revolution Medicines, Inc.

Phase 3

900

Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama

2026-03-09

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Aichi, Bunkyō City, Chiba, Chūō, Fuchū, Fukuoka, Fukushima, Isehara

2026-03-05

Recruiting

First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

NCT07679061Unresectable Hepatocellular Carcinoma

Bristol-Myers Squibb

Observational

200

Minato-ku, Chiba

2026-03-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Akashi-shi, Chiba, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kawasaki-shi, Kita-gun

2026-03-05

Recruiting

MSA-01 in Multiple System Atrophy

NCT07446894Multiple System Atrophy (MSA)

Tokyo University

Phase 3

140

Nagoya, Chiba, Fukuoka, Sapporo, Kagoshima, Kyoto, Okayama, Hasuda

2026-02-09

Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931Osteoarthritis, Overweight or Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima

2026-02-09

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

400

Bunkyō City, Chiba, Kamakura-shi, Kamogawa, Kofu, Minato, Shibuya City, Yokohama

2026-02-04

Recruiting

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)

NCT07340827Infertility

DrugsGnRH·Progesterone

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

266

Akita, Chiba, Maebashi, Sapporo, Kobe, Sagamihara-shi, Kochi, Nagano

2026-02-04

Recruiting

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07271069Ulcerative Colitis (UC)

DrugsOzanimod·Azathioprine

Bristol-Myers Squibb

Observational

150

Chiba, Kashiwa-shi, Sakura, Matsuyama, Chikushino-shi, Fukuoka, Asahikawa, Sapporo

2026-01-29

Recruiting

Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)

NCT07671885Breast Cancer

Tokyo Women's Medical University

Phase 3

950

Akita, Chiba, Fukuoka, Fukushima, Fukuyama, Hamamatsu, Hirakata, Hiroshima

2026-01-28

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Nagoya, Chiba, Matsuyama, Kurume, Otashi, Asahikawa, Sapporo, Kobe

2026-01-06

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Nagoya, Toyoake, Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Yokohama

2025-12-31

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336Breast Neoplasms, Neoplasm Metastasis

DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib

Eli Lilly and Company

Phase 3

800

Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima

2025-12-22

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

DrugCetuximab

Revolution Medicines, Inc.

Phase 3

500

Yokohama, Chiba, Fukuoka, Kyoto, Tokyo

2025-12-15

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Nagoya, Chiba, Kashiwa, Yokohama, Hidaka, Kitaadachi-gun, Nagaizumi-cho, Koto-ku

2025-12-11

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi

2025-12-04

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Kumamoto, Miyagi, Osaka

2025-12-03

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

DrugRina-S

Genmab

Phase 3

660

Chiba, Ōta, Shiwa-gun, Sagamihara-shi, Yokohama, Tsu, Sendai, Osaka

2025-11-28

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

Osaka, Aichi, Chiba, Ehime, Fukuoka, Gifu, Hiroshima, Hokkaido

2025-11-18

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku

2025-10-30

Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms

Eli Lilly and Company

Phase 1

241

Chiba, Kyoto

2025-10-22

Recruiting

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT07213609Neoplasms, Colorectal, Neoplasms

GlaxoSmithKline

Phase 1/2

Chiba, Osaka, Tokyo

2025-10-20

Recruiting

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

NCT07136116Ulcerative Colitis

AbbVie

Observational

200

Nagakute, Nagoya, Hirosaki, Chiba, Kashiwa-shi, Sakura, Fukuoka, Hiroshima

2025-10-09

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Nagoya, Chiba, Kashiwa, Kita-gun, Kawasaki, Yokohama, Suita, Nagaizumi-cho

2025-10-03

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Chiba, Fukui-shi, Gamagōri, Hamamatsu, Higashiibaraki-gun, Hiroshima, Kagawa, Kagoshima

2025-10-03

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Chiba, Chūōku, Fujiidera-shi, Fukui-shi, Fukuoka, Gamagōri, Hamamatsu, Higashiibaraki-gun

2025-10-01

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

Chiba, Fuchū, Niigata, Sagamihara, Sanda-shi, Sendai

2025-09-30

Recruiting

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

NCT07202884Urinary Incontinence,Stress

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,000

Arakawa City, Chiba, Chiyoda City, Chūōku, Higashiibaraki, Itabashiku, Kitakyushu, Matsudo

2025-09-30

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Chiba, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka, Suita

2025-09-28

Active, closed

Fabhalta Capsules Specified Drug-use Survey

NCT07156149C3 Glomerulopathy

Novartis Pharmaceuticals

Observational

Nagoya, Toyoake, Hirosaki, Chiba, Fukuoka, Kitakyushu, Sapporo, Tsukuba

2025-09-17

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Nagoya, Chiba, Matsuyama, Otashi, Sapporo, Kanazawa, Isehara, Yokohama

2025-09-11

Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms

Eli Lilly and Company

Phase 1

421

Chiba, Kyoto, Osaka

2025-08-06

Not yet open

Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis

NCT07106346Walled Off Necrosis, Pancreatitis, Acute Necrotic Collection, Necrotizing Pancreatitis

Tokyo University

Not applicable

224

Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kagawa, Kagoshima

2025-08-05

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

Chiba, Kashiwa, Matsuyama, Otashi, Isehara, Yokohama, Suita, Bunkyo-ku

2025-08-05

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Nagoya, Toyoake-shi, Chiba, Sapporo, Naka, Toride-shi, Tsuchiura-shi, Kanazawa

2025-07-25

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)

DrugsEYLEA (aflibercept)·4D-150 IVT

4D Molecular Therapeutics

Phase 3

480

Nagoya, Hyōgo, Fukushima, Mito, Miyazaki, Ginowan, Chiba, Fukuoka

2025-07-22

Recruiting

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

NCT07015697Recurrent or Metastatic Solid Tumors

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 1

Chiba, Kanagawa, Tokyo

2025-07-17

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Kasugai-Shi, Nagoya, Toyoake-shi, Chiba, Fukuoka, Fukushima, Hiroshima, Sapporo

2025-07-15

Active, closed

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Sapporo, Yokohama, Bunkyo-ku, Shinjuku-ku, Chiba, Fukuoka, Okayama, Osaka

2025-07-14

Recruiting

ELEVATE-HFpEF Clinical Study

NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)

Medtronic Cardiac Rhythm and Heart Failure

Not applicable

700

Chiba, Kitakyushu, Suita

2025-07-09

Recruiting

Cities for Better Health Childhood Obesity Prevention Initiative in JAPAN

NCT07061665Quality of Life (QOL), Nutrition, Physical Activity, Obesity

Chiba University

Not applicable

2,200

Chiba

2025-07-07

Recruiting

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277Prostate Cancer

DrugsAAA817·ARPI

Novartis Pharmaceuticals

Phase 3

940

Nagoya, Sapporo, Kobe, Kamakura, Yokohama, Kumamoto, Chuo Ku, Chiba

2025-07-01

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Chiba, Fukuoka, Fukushima, Ginowan-shi, Hachioji-shi, Hamamatsu, Hiroshima, Izumi-shi

2025-06-27

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Toyoake-shi, Chiba, Fukuoka, Kitakyushu-shi, Sapporo, Himeji-shi, Takarazuka-shi, Kanazawa

2025-06-25

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

981

Kitakyushu-shi, Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki

2025-06-20

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

346

Aichi, Chiba, Hokkaido, Osaka, Tokyo

2025-06-11

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Chiba, Sapporo, Kyoto, Bunkyō-Ku

2025-06-09

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Chiba, Kashiwa, Matsuyama, Fukuoka, Maebashi, Sapporo, Akashi-shi, Kobe

2025-05-22

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

Toyoake-shi, Hirosaki-shi, Chiba, Urayasu-Shi, Sapporo, Kitakyushu-shi, Fukushima, Kawasaki-shi

2025-05-08

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe

2025-05-06

By invitation

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

NCT06831734Haemophilia A, Haemophilia B

DrugConcizumab

Novo Nordisk A/S

Observational

Chiba, Fukui, Fukushima, Hyōgo, Kanagawa, Kawagoe, Miyagi, Nagano

2025-05-02

By invitation

Cities for Better Health Childhood Obesity Prevention Initiative

NCT06855563Obesity

Novo Nordisk A/S

Not applicable

36,000

Chiba

2025-04-30

Active, closed

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

NCT06881836Alzheimer Disease

DrugONO-2020

Ono Pharmaceutical Co., Ltd.

Phase 2

260

Aichi, Chiba, Fukushima, Gunma, Hiroshima, Hyōgo, Ibaraki, Kagawa

2025-04-24

Active, closed

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

NCT06704269Generalized Myasthenia Gravis

Novartis Pharmaceuticals

Phase 1/2

Chiba, Kyoto

2025-04-22

Recruiting

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

NCT06807190Diabetes Mellitus, Type 1

DrugInsulin icodec

Novo Nordisk A/S

Observational

630

Koriyama-shi, Fukushima, Oita-shi, Oita,, Kumamoto, Aichi, Aomori, Chiba, Chitose, Hokkaido, Ehime

2025-04-15

Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671CLL, Chronic Lymphocytic Leukemia

DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax

BeOne Medicines

Phase 3

250

Nagoya, Chiba, Matsuyama, Hiroshima, Sapporo, AmagasakiCity, Kagoshima, KyotoShi

2025-04-10

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

Shimotsuke-shi, Bunkyo-Ku, Chiba

2025-04-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Aichi, Chiba, Fukushima, Hiroshima, Hokkaido, Kanagawa, Okayama, Saitama

2025-04-09

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe

2025-04-04

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Asahikawa-shi, Takamatsu, Sendai, Aichi, Aomori, Chiba, Chikushino-shi, Ehime

2025-03-17

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290ANCA Associated Vasculitis (AAV)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

126

Chiba, Sapporo, Kobe, Sendai, Suita, Bunkyo Ku, Shinjuku-ku, Fukuoka

2025-03-13

Active, closed

Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries

NCT06938854Peripheral Arterial Disease

Shockwave Medical, Inc.

Not applicable

Asahi, Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Miyagi, Nara

2025-03-10

Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 3

300

Nagoya, Toyohashishi, Chiba, Matsuyama, Ōgaki, Hiroshima, Sapporo, KobeShi

2025-03-05

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

Chiba, Fukuoka, Tokyo

2025-03-04

Recruiting

Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy

NCT06862596Spinal and Bulbar Muscular Atrophy

Masahisa Katsuno

Phase 2/3

Bunkyō City, Chiba, Sapporo, Shimotsuke, Suita

2025-02-28

Active, closed

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212Schizophrenia

DrugUlotaront

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

538

Konan-shi, Toyoake-shi, Hachinohe-shi, Chiba, Ichikawa-shi, Fukuoka, Kokuraminami-ku, Kitakyushu-shi, Omuta-shi

2025-02-28

Recruiting

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670Prostate Cancer

DrugAAA817

Novartis Pharmaceuticals

Phase 2/3

443

Kashiwa, Sapporo, Kobe, Yokohama, Chiba, Fukuoka, Fukushima, Ishikawa

2025-02-27

By invitation

ClotTriever® Thrombectomy System Use-Result Survey in Japan

NCT06871683Deep Vein Thrombosis

Inari Medical

Observational

100

Chuo, Ōta, Kawasaki, Suita, Asahikawa, Chiba, Daitō, Kanagawa

2025-02-17

Active, closed

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053Asthma

DrugGSK5784283

GlaxoSmithKline

Phase 2

307

Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima, Hokkaido, Hyōgo

2025-02-10

Active, closed

A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

NCT06730061Primary Biliary Cholangitis

DrugElafibranor

Ipsen

Phase 3

Chiba, Fukushima, Hiroshima, Hokkaido, Kagawa, Kagoshima, Nagano, Nagasaki

2025-01-16

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

Chiba, Chūōku, Hirakata, Hyōgo, Kitakyushu-shi, Nagoya, Osaka, Ōita

2025-01-09

Active, closed

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer

GlaxoSmithKline

Phase 1/2

Chiba, Shizuoka, Tokyo

2024-12-13

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Chiba, Chūōku, Kashiwa, Nagoya, Osaka, Sakai, Shizuoka, Suita

2024-12-12

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama

2024-11-27

Recruiting

Study to ONO-4538 in Patients With Rhabdoid Tumor

NCT06622941Rhabdoid Tumor

DrugNivolumab

Ono Pharmaceutical Co., Ltd.

Phase 2

Nagoya, Sapporo, Kobe, Osaka, Chuo-ku, Chiba, Fukuoka, Fukushima

2024-11-25

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Akita, Aomori, Bunkyō City, Chiba, Fukuoka, Fukuyama, Gifu, Hamamatsu

2024-11-19

Recruiting

Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis

NCT06611696ANCA Associated Vasculitis (AAV)

Chiba University

Phase 4

160

Toyoake, Asahi, Chiba, Ichihara, Kamogawa, Narita, Maebashi, Hiragi

2024-11-15

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

Bunkyō City, Chiba, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu, Gifu, Ogaki

2024-11-12

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Chiba, Hokkaido, Hyōgo, Kagawa, Kumamoto, Osaka, Tokyo, Yamanashi

2024-11-11

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka

2024-10-22

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

600

Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka

2024-10-21

Active, closed

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab

Eli Lilly and Company

Phase 1

750

Chiba, Kyoto, Shizuoka, Tokyo

2024-10-21

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Chiba, Chūōku, Kashiwa, Nagoya, Osaka, Shizuoka, Suita, Tokyo

2024-10-18

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Cetuximab

Revolution Medicines, Inc.

Phase 3

500

Chiba, Nagoya, Osaka, Tokyo, Yokohama

2024-10-16

Active, closed

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844Non-small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Vinorelbine·Etoposide

AstraZeneca

Phase 3

Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Iwakuni-shi, Kashiwa

2024-10-15

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

Bunkyō City, Chiba, Chiba, Ichikawa, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu

2024-10-14

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugMirikizumab

Eli Lilly and Company

Phase 2

143

Chiba, Chikushino-shi, Fukuoak, Hachinohe-shi, Hirosaki, Hiroshima, Isehara, Isesaki-shi

2024-10-10

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286HIV-1-infection

DrugsISL/LEN·B/F/TAF

Gilead Sciences

Phase 3

609

Chiba, Nagoya, Okinawa, Osaka, Osaka Fu, Tokyo

2024-10-09

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Chiba, Nagoya, Okinawa, Osaka, Osaka Fu, Tokyo

2024-10-08

Active, closed

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

349

Chiba, Fuchū, Gifu, Niigata, Sagamihara, Sanda-shi, Sendai

2024-10-02

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Aichi, Chiba, Shizuoka, Tokyo

2024-09-30

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Chiba, Ehime, Gunma, Hokkaido, Kagawa, Nara, Niigata, Osaka

2024-09-27

Active, closed

Specified Drug-use Surveillance of Fabhalta Capsules

NCT06606314Paroxysmal Nocturnal Hemoglobinuria

Novartis Pharmaceuticals

Observational

132

Handa, Nagoya, Okazaki, Toyohashi, Toyota, Hachinohe, Chiba, Funabashi

2024-09-18

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima, Kanagawa, Nagasaki

2024-09-17

Active, closed

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Eli Lilly and Company

Phase 1

630

Chiba, Kanagawa, Nagoya, Osaka, Tokyo

2024-09-12

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Chiba, Sapporo, Kobe, Yokohama, Sendai, Suita, Izumo, Bunkyo Ku

2024-09-04

Active, closed

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

NCT06531824Kidney Disease, Chronic

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

8,371

Asahikawa-Shi, Chiba, Chuo-Shi, Fukuoka, Isehara, Izumo, Kurashiki-Shi, Kurume

2024-08-30

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Chiba, Hyōgo, Kanagawa, Mie, Okayama, Saitama, Shizuoka, Tokyo

2024-08-28

Active, closed

Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings

NCT06561958Infertility

DrugRekovelle

Ferring Pharmaceuticals

Observational

1,526

Chiba, Fukuoka, Kitakyushu, Takasaki, Hiroshima, Bunkyō City, Tokyo, Hokkaido

2024-08-27

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Yokohama, Higashi-Matsuyama, Kawagoe, Yaizu, Kodaira, Ōta-ku, Amagasaki, Chiba

2024-08-21

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Isesaki-shi, Kagoshima, Kyoto

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Bunkyō City, Chiba, Fukuyama-shi, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi

2024-08-12

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto

2024-08-07

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto

2024-08-01

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Chiba, Narita, Sapporo, Nishinomiya, Hanamaki, Sendai, Suita, Higashi-Matsuyama

2024-07-31

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Nagoya, Chiba, Kashiwa, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kagoshima

2024-07-19

Recruiting

Revolade Tablets Specified Drug-use Survey

NCT06287268Aplastic Anemia

Novartis Pharmaceuticals

Observational

Nagoya, Toyoake, Chiba, Amagasaki, Kobe, Matsumoto, Shimajiri-Gun, Izumi

2024-07-17

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsAvutometinib·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Akashi-shi, Kawasaki-shi

2024-07-17

Active, closed

Fasenra Pediatric Japan Post-Marketing Study(PMS)

NCT06427876Bronchial Asthma

AstraZeneca

Observational

Chiba, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Mie, Okayama, Osaka

2024-07-16

Active, closed

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

109

Sayama, Kawagoe, Yaizu, Bunkyo-Ku, Kodaira, Chiba, Fukuoka, Saga

2024-07-12

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

Chiba, Narita-shi, Fukuoka, Koriyama-shi, Hakodate-shi, Hanamaki-shi, Kita-gun, Nagasaki

2024-06-25

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Miyazaki, Aichi, Chiba, Ehime, Fukuoka, Fukuoka-shi, Fukuoka, Himeji-shi, Hyogo, Hokkaido

2024-06-25

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Asahikawa-Shi, Bunkyō City, Chiba, Fukuoka, Hiroshima, Iruma-Gun, Kawachinagano-shi, Kawasaki-shi

2024-06-20

Active, closed

Special Use - Results Surveillance on Long-term Use With Wegovy®

NCT06283667Obesity

DrugsWegovy·Semaglutide

Novo Nordisk A/S

Observational

1,071

Tokyo, Kumamoto, Aichi, Akita, Akita-shi, Akita, Aomori, Bunkyo-ku, Tokyo, Chiba

2024-06-11

Recruiting

Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)

NCT06436092Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina

TCROSS Co., Ltd.

Observational

280

Ichinomiya, Toyoake, Chiba, Matsudo, Urayasu, Matsuyama, Fukuoka, Kitakyushu

2024-05-27

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Anjo, Nagoya, Chiba, Yoshida-gun, Fukuoka, Gifu, Maebashi, Fukuyama

2024-05-19

Active, closed

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

NCT06317311Carcinoma

DrugsDostarlimab·Paclitaxel·Carboplatin

GlaxoSmithKline

Phase 2

Aichi, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo, Ibaraki

2024-05-07

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Aichi, Chiba, Chūō, Fukui, Fukuoak, Fukuoka, Habikino-shi, Hirakata

2024-04-29

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Chiba, Morioka, Sagamihara-shi, Kyoto, Sendai, Moriguchi-shi, Osaka, Kawagoe-shi

2024-04-16

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Bunkyō City, Chiba, Fukuoka, Kamakura, Kasugai-shi, Kitakyushu-shi, Kobe, Matsumoto-shi

2024-03-29

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

Aichi, Aomori, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo

2024-03-21

Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06297226Multiple Myeloma

DrugArlo-cel

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

230

Nagoya, Nishinomiya, Shibuya-ku, Chiba, Kyoto

2024-03-21

Active, closed

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

DrugsTecartus·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 2

Chiba, Fukuoka, Hokkaido, Kyoto, Miyagi, Okayama, Tokyo

2024-03-18

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Bunkyō City, Chiba, Fuchu-shi, Kawasaki-shi, Kobe, Nagasaki, Obu-shi, Shinjuku-ku

2024-03-14

Active, closed

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

NCT05930275Crohn's Disease

AbbVie

Observational

1,200

Nagoya, Toyoake, Hirosaki, Chiba, Sakura, Fukuoka, Fukushima, Asahikawa-shi

2024-02-19

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

NCT06262919BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

DrugDabrafenib/trametinib

Novartis Pharmaceuticals

Observational

110

Nagakute, Nagoya, Toyohashi, Toyota, Daisen, Chiba, Funabashi, Kashiwa

2024-02-09

Active, closed

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632Advanced or Metastatic Breast Cancer

DrugsExemestane·Everolimus·Fulvestrant

Pfizer

Phase 2

333

Otashi, Sendai, Suita, Chuo-ku, Chiba, Hiroshima, Osaka

2024-01-09

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160Solid Tumors

DrugsGEMNabP·INCA33890·INCB161734·Retifanlimab

Incyte Corporation

Phase 1

710

Chiba, Tokyo

2024-01-04

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka

2023-12-29

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Kōriyama, Asahikawa, Himeji, Sagamihara, Higashi-Matsuyama, Kodaira, Chiba, Fukuoka

2023-12-27

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe

2023-12-14

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi

2023-11-23

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Chiba, Fukuoka, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kisarazu-shi

2023-11-21

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsAvutometinib·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Nagoya, Hirosaki-shi, Chiba, Kashiwa-shi, Matsuyama, Toon-shi, Fukuoka, Kitakyushu-shi

2023-11-16

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Aichi, Chiba, Hyōgo, Osaka, Saitama, Shizuoka, Tokyo

2023-11-14

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Akashi-shi, Akita, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu

2023-11-14

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Saitama-Shi Chuo-Ku, Aoi-ku, Setagaya-Ku, Chiba, Izumi-Shi

2023-11-13

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Nagoya, Chiba, Matsuyama, Sapporo, AmagasakiCity, Kagoshima, Iseharashi, Sendai

2023-11-11

Not yet open

WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts

NCT06133023Pancreatic Fluid Collection, Pancreatitis, Pancreatic Pseudocyst

Tokyo University

Not applicable

Aichi, Bunkyō-Ku, Tokyo, Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima

2023-11

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Showa-Ku, Toyoake-shi, Chiba, Kamogawa-shi, Yoshida-gun, Chikushino-shi, Fukuoka, Koriyama-shi

2023-10-25

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Nagoya, Sapporo, Nishinomiya, Kanazawa, Isehara, Shibuya-ku, Chiba, Fukuoka

2023-10-16

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun

2023-10-05

By invitation

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

NCT06109935Growth Hormone Deficiency in Children

DrugSomapacitan

Novo Nordisk A/S

Observational

200

Aichi, Aomori, Asahikawa, Hokkaido, Beppu-shi, Oita-ken, Chiba, Fukuoka, Fukuoka-shi, Fukuoka-ken, Fukuoka-shi, Fukuoka

2023-10-04

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Chiba, Kashiwa-shi, Kanazawa, Yokohama, Osakasayama-shi

2023-09-21

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Nagakute, Chiba, Kamogawa, Kashiwa-shi, Kurume, Ōgaki, Maebashi, Shibukawa

2023-09-18

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Kyoto

2023-09-18

Active, closed

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886Hepatocellular Carcinoma

DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

687

Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Ishikawa, Kanagawa

2023-09-14

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Chiba, Fukuoka, Koriyama-shi, Naka-gun, Hiroshima, Sapporo, Himeji-Shi, Kobe

2023-09-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama

2023-09-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Aichi, Aomori, Chiba, Chūō, Ehime, Fukuoka, Hiroshima, Hokkaido

2023-08-08

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Aichi, Chiba, Fukuoka, Hokkaido, Hyōgo, Ibaraki, Kanagawa, Kyoto

2023-08-01

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Shibukawa-shi, Kamakura-Shi, Kumamoto, Sunto-gun, Chiba, Gifu, Hiroshima, Isehara-shi

2023-06-22

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

Chiba, Osaka, Tokyo, Wakayama

2023-06-20

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Dexamethasone

GlaxoSmithKline

Phase 1/2

123

Aomori, Chiba, Kanagawa, Osaka, Tokyo, Yamagata

2023-06-14

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Nagoya, Hirosaki-shi, Chiba, Sakura-shi, Chikushino-shi, Fukuoka, Asahikawa-shi, Sapporo

2023-06-09

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

Chiba, Kanazawa, Osaka, Tokushima, Tottori

2023-06-07

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

NCT05862285Cancer

DrugsTiragolumab and Atezolizumab·Divarasib·Tiragolumab·Ipatasertib

Hoffmann-La Roche

Phase 3

100

Chiba, Fukuoka, Kanagawa, Kashiwa-shi, Saitama, Sakaishi

2023-06-01

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Aichi, Aoba-ku, Bunkyō City, Chiba, Chūōku, Ehime, Fukushima, Kagoshima

2023-05-08

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

Aichi, Bunkyō City, Chiba, Chikushino-shi, Fukuoka, Funabashi-shi, Gifu, Higashiibaraki-gun

2023-04-11

Active, closed

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

NCT05729711Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

AstraZeneca

Observational

416

Aichi, Akita, Aomori, Chiba, Fukui, Fukuoka, Gifu, Gunma

2023-04-04

Active, closed

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562Neoplasms, Rectal

DrugDostarlimab

GlaxoSmithKline

Phase 2

154

Chiba, Kanagawa, Osaka

2023-04-03

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi

2023-03-31

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Relapsed or Refractory Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Bunkyō City, Chiba, Gifu, Gunma, Hirakata, Hitachi, Iruma-gun, Kamogawa

2023-03-29

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Nagoya, Chiba, Kashiwa, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yahaba

2023-03-15

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Nagoya, Chiba, Kashiwa, Sapporo, Yokohama, Suita, Ina-machi, Bunkyo-ku

2023-03-03

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Chiba, Chikushino-shi, Fukuoka, Gifu, Hachiōji, Hamamatsu, Hatsukaichi, Hidaka

2023-02-15

Active, closed

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

226

Nagakute, Shibukawa, Sapporo, Okayama, Iruma-gun, Chiba, Fukuoka, Gifu

2023-02-03

Active, closed

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

513

Nagoya, Toyoake, Chiba, Eiheiji-cho,Yoshida-gun, Kitakyushu, Asahikawa, Sapporo, Kita

2023-01-12

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Chiba, Nagoya, Tokyo

2023-01-12

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

DrugBlinatumomab

Princess Maxima Center for Pediatric Oncology

Phase 3

160

Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto

2022-12-15

Active, closed

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

470

Amagasaki-shi, Bunkyō City, Chiba, Chuo-shi, Chūōku, Fukuoka, Hiroshima, Hitachi-Naka

2022-12-13

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Chiba, Fukuoka, Gifu, Ginowan-shi, Hanyu-shi, Hiroshima, Hitachi-shi, Isehara-shi

2022-12-13

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine

Gilead Sciences

Phase 3

1,514

Chiba, Tokyo

2022-12-12

Active, closed

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777Cough, Refractory Chronic Cough

DrugCamlipixant

Bellus Health Inc. - a GSK company

Phase 3

997

Aichi, Akita, Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima

2022-12-05

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Akashi-shi, Chiba, Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kashiwa

2022-11-28

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Chiba, Fukushima, Higashimatsuyama-shi, Isehara-shi, Itabashi-ku, Kawasaki-shi, Morioka, Nagasaki

2022-11-21

Recruiting

TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer

NCT05646511Locally Advanced Rectal Cancer

DrugFolfox

National Cancer Center Hospital East

Phase 3

608

Chiba, Ehime, Fukuoka, Gifu, Hirosaki, Hiroshima, Kawasaki, Kitakyushu

2022-11-21

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Bunkyō City, Chiba, Higashiibaraki-gun, Hirakata, Hyôgo, Iruma-gun, Kanagawa, Kanazawa

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kobe, Kita-gun, Kawasaki-shi

2022-10-24

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Chiba, Fukuoka, Hyōgo, Kanagawa, Osaka, Saitama

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Bunkyō City, Chiba, Fukuoka, Gifu, Gunma, Hirakata, Hyōgo, Kamakura-shi

2022-10-13

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

Chiba, Ehime, Fukuoka, Hyōgo, Ishikawa, Kanagawa, Miyagi, Niigata

2022-10-12

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Fukuyama, Gifu, Hachioji-shi

2022-10-04

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis

DrugSatralizumab

Hoffmann-La Roche

Phase 3

122

Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Miyagi

2022-09-27

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Asahikawa, Bunkyō City, Chiba, Hamamatsu, Isehara, Kobe, Kodaira-shi, Koshigaya

2022-09-23

Active, closed

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327Systemic Lupus Erythematosus

DrugEnpatoran

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2

381

Asahikawa-shi, Chiba, Chūōku, Hiroshima, Kagoshima, Kawagoe-shi, Kita-gun, Sapporo

2022-09-16

Active, closed

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368Hypereosinophilic Syndrome

DrugDepemokimab

GlaxoSmithKline

Phase 3

110

Aomori, Chiba, Gifu, Hyōgo, Miyagi, Tokyo, Wakayama, Yamanashi

2022-09-06

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

NCT05271409Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

DrugSatralizumab

Hoffmann-La Roche

Phase 3

139

Chiba, Fukuoka, Fukushima, Hyōgo, Kanagawa, Miyagi, Osaka, Tokyo

2022-08-30

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Chiba, Kanagawa, Tokyo

2022-08-03

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus

Genentech, Inc.

Phase 3

373

Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kanagawa

2022-08-03

Recruiting

Immediate Necrosectomy vs. Step-up Approach for Walled-off Necrosis

NCT05451901Pancreatic Fluid Collection, Walled-off Necrosis, Pancreatitis, Acute Necrotizing, Pancreatic Pseudocyst

Tokyo University

Not applicable

Bunkyō-Ku, Aichi, Chiba, Gifu, Hyōgo, Kagawa, Kagoshima, Kamogawa

2022-07-29

Recruiting

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

NCT05265273Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

Azumino-shi, Chiba, Miyazaki, Nishinomiya-Shi, Saitama Shi, Shinjuku-ku

2022-07-20

Active, closed

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 1

160

Chiba, Ōsaka-sayama, Chūō, Koto-Ku

2022-06-30

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Matsuyama, Higashi-Ibaraki-gun, Shimotsuga, Nerima-ku, Shinagawa-ku, Chuo-shi, Aomori, Chiba

2022-06-23

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Nagoya, Toyoake-shi, Chiba, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo, Himeji-shi

2022-06-10

Recruiting

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

NCT05454787Life Threatening Bleeding, Factor Xa Inhibitor

AstraZeneca

Observational

300

Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima

2022-06-02

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Kasugai, Toyoake, Chiba, Ichihara, Higashi, Yokohama, Asahikawa, Sapporo

2022-05-30

Recruiting

Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence

NCT04976153Fecal Incontinence

Innovacell GmbH

Phase 3

290

Sapporo, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kumamoto, Kyoto

2022-05-11

By invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2/3

600

Nagoya, Toyoake-shi, Chiba, Urayasu-shi, Kobe, Tsukuba, Kawasaki-shi, Kashihara

2022-04-05

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Chiba, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kita-gun, Kobe, Kumamoto

2022-03-25

Active, closed

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051Neoplasms

DrugsRemzistotug·GSK5764227·Nelistotug·Belrestotug

GlaxoSmithKline

Phase 1

152

Chiba, Tokyo

2022-03-22

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka

2022-02-21

Active, closed

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895Non-Small Cell Lung Cancer

DrugsDomvanalimab·Durvalumab

AstraZeneca

Phase 3

791

Bunkyō City, Chiba, Fukuoka, Hidaka-shi, Hirosaki-shi, Itabashi-ku, Kashihara-shi, Kōtoku

2022-02-18

Active, closed

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133Lupus Nephritis

DrugAnifrolumab

AstraZeneca

Phase 3

363

Bunkyō City, Chiba, Hiroshima, Kita-gun, Kitakyushu-shi, Matsumoto-shi, Nagasaki, Okayama

2022-02-15

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

Chiba, Fukuoka, Gunma, Hiroshima, Hyōgo, Ishikawa, Kanagawa, Niigata

2022-02-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

DrugRozanolixizumab

UCB Biopharma SRL

Phase 3

113

Chiba, Isehara, Kitakyushu-shi, Kodaira, Koriyama-shi, Sendai, Shinjuku-ku, Suita-shi

2022-02-02

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasaki, Osaka, Ōita

2022-01-15

Active, closed

A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

NCT05114759Advanced Solid Tumors

DrugSHR-A2009

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

176

Chiba, Tokyo

2022-01-04

Active, closed

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

NCT05141201Lupus Erythematosus, Systemic

AstraZeneca

Observational

1,620

Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima

2021-12-21

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Nagoya, Chiba, Ichihara, Fukuoka, Sapporo, Kobe, Nishinomiya, Isehara

2021-12-13

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Chiba, Kashiwa-shi, Gifu, Ota-shi, Akashi-shi, Kasama-Shi, Kita-Gun Miki-Cho, Yokohama-Shi Asahi-Ku

2021-12-02

Active, closed

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

NCT05245968Gastrointestinal Stromal Tumors

DrugsPimitespib·Sunitinib·Imatinib

Taiho Pharmaceutical Co., Ltd.

Phase 1

Chiba, Hokkaido, Kumamoto, Osaka, Tokyo

2021-12-01

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Aichi, Chiba, Kyoto, Mie, Miyagi, Okayama, Tokyo

2021-10-27

Active, closed

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

NCT05101096Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer

DrugSacituzumab Govitecan

Gilead Sciences

Phase 1/2

135

Aichi, Akita, Aoba-ku, Aomori, Asahi-ku, Bunkyō City, Chiba, Chūōku

2021-10-20

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Chiba, Eiheiji-cho,Yoshida-gun, Kitakyushu, Fukushima, Sapporo, Kanazawa, Sendai, Bunkyo-ku

2021-10-11

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Nagoya, Chiba, Matsuyama, Kurume, Otashi, Sapporo, Akashi, Kobe

2021-10-04

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Nagoya, Chiba, Yoshida-Gun, Sapporo, Nankoku, Sendai, Koshigaya, Chūō

2021-09-23

Active, closed

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

NCT06540261Unresectable Colorectal Cancer

DrugsMagrolimab·Levofolinate·Fluorouracil·Cetuximab

Ono Pharmaceutical Co., Ltd.

Phase 1

Toyoake, Chiba, Kashiwa, Sapporo, Kobe, Kawasaki, Yokohama, Kurashiki

2021-09-23

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Nagoya, Chiba, Kashiwa, Kotoku, Yokohama

2021-09-13

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Akishima-shi, Amagasaki-shi, Asahi-shi, Bunkyō City, Chiba, Chikushino-shi, Chūō, Daito-shi

2021-08-14

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

562

Nagoya, Toyoake-shi, Chiba, Narashino-shi, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo

2021-07-16

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Chiba, Hanamaki, Hiroshima, Itabashi Ku, Kawasaki Shi, Kita Gun, Kumamoto, Nagoya

2021-07-15

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama

2021-06-30

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Kagoshima, Kanagawa

2021-06-28

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Nishinomiya, Kawasaki, Sagamihara, Suita, Hidaka, Shinjuku-ku, Chiba, Fukuoka

2021-06-18

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Chiba, Chūōku, Hamamatsu, Hiroshima, Itabashi-ku, Kita-gun, Kitakyushu-shi, Meguro-ku

2021-06-08

Recruiting

AB122 Platform Study

NCT04999761Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer

DrugsPimitespib·Futibatinib·Domvanalimab·Ramucirumab

Taiho Pharmaceutical Co., Ltd.

Phase 1

917

Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo

2021-06-01

Active, closed

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293Autoimmune Pulmonary Alveolar Proteinosis

DrugMolgramostim

Savara Inc.

Phase 3

164

Chiba, Sapporo, Yokohama, Kumamoto, Sendai, Sakai, Saitama, Mitaka

2021-05-19

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Nagoya, Hirosaki, Chiba, Kashiwa, Matsuyama, Fukuoka, Kure, Sapporo

2021-05-12

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto

2021-05-10

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Ibaraki, Kanagawa, Kyoto

2021-05-03

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima

2021-04-26

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Atezolizumab·Lenvatinib

Hoffmann-La Roche

Phase 3

557

Aichi, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Osaka, Tochigi

2021-04-26

Recruiting

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

NCT04674969Peripheral Vascular Diseases

Boston Scientific Corporation

Observational

5,000

Sapporo, Kyoto, Miyazaki, Aichi, Chiba, Osaka

2021-03-29

Active, closed

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

NCT04712643Hepatocellular Carcinoma

DrugsTecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

342

Aichi, Chiba, Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo

2021-03-12

Active, closed

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm

DrugRuxolitinib

Incyte Corporation

Phase 1

140

Aichi, Chiba, Chūō, Fukuoka, Kumamoto

2021-02-23

Active, closed

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

277

Kashiwa, Tokyo, Matsuyama, Sapporo, Akashi, Chiba, Ariake, Sendai

2021-02-02

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Chiba, Fukuoka, Gifu, Hokkaido, Kobe, Koshigaya, Kumamoto, Kurashiki

2021-02-01

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto

2021-01-28

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Chiba, Kashiwa, Sapporo, Kanazawa, Kawasaki, Yokohama, Nagoya, Osaka

2020-12-21

Active, closed

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

NCT04641442NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

DrugArumakimig

Novartis Pharmaceuticals

Phase 2

Chiba

2020-12-18

Active, closed

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin

AstraZeneca

Phase 3

358

Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata

2020-12-16

Active, closed

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

NCT04661007Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma

DrugsParsaclisib·Tafasitamab·R-Chop·Lenalidomide

Incyte Biosciences Japan GK

Phase 1/2

Aichi, Chiba, Fukui, Fukuoka, Hyōgo, Kanagawa, Kōtoku, Kumamoto-ken

2020-12-15

Active, closed

Myasthenia Gravis Inebilizumab Trial

NCT04524273Myasthenia Gravis

DrugInebilizumab

Amgen

Phase 3

238

Chiba, Fukuoka, Hokkaido, Hyōgo, Miyagi, Moriguchi, Morioka, Saitama

2020-10-15

Active, closed

CHAMPION-AF Clinical Trial

NCT04394546Atrial Fibrillation, Stroke, Bleeding

DrugsNon-Vitamin K Anticoagulant·NOAC

Boston Scientific Corporation

Not applicable

3,000

Chiba, Kitakyushu-shi, Shiwa-gun, Chiyoda-ku, Okamoto, Okayama, Tokyo, Toyama

2020-10-15

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima

2020-10-09

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Chiba, Chūōku, Fukuoka, Itabashi-ku, Kahoku-gun, Kashiwa, Kobe, Kōtoku

2020-10-08

Active, closed

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone

GlaxoSmithKline

Phase 3

302

Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Numakunai, Okayama

2020-10-01

Active, closed

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

DrugEfgartigimod PH20

argenx

Phase 2

229

Bunkyō City, Chiba, Fuchū, Fukuoka, Ginowan, Hakodate, Hiroshima, Kawagoe

2020-09-18

Active, closed

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691Advanced or Metastatic NSCLC

DrugsDato-DXd·Keytruda·Cisplatin·Carboplatin

Daiichi Sankyo

Phase 1

145

Chiba, Tokyo

2020-09-15

Recruiting

ONO-4538 Phase II Rollover Study (ONO-4538-98)

NCT04566380Pan-tumor

DrugsBinimetinib·Teysuno·Temozolomide·Ipilimumab

Ono Pharmaceutical Co., Ltd.

Phase 2

Chiba, Kashiwa, Matsuyama, Fukuoka, Kurume, Hiroshima, Sapporo, Akashi

2020-09-10

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

Nagoya, Toyoake, Aomori, Chiba, Kashiwa-shi, Toon-shi, Fukuoka, Fukushima

2020-08-31

Active, closed

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma

DrugsRituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab·Lenvatinib

Genmab

Phase 1/2

Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto

2020-08-20

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima

2020-07-24

Active, closed

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304Hypereosinophilic Syndrome

DrugBenralizumab

AstraZeneca

Phase 3

134

Chiba, Hamamatsu, Ichikawa-shi, Kawasaki-shi, Nishinomiya-shi, Osaka, Sendai

2020-07-20

Active, closed

Linerixibat Long-term Safety, and Tolerability Study

NCT04167358Cholestasis

GlaxoSmithKline

Phase 3

242

Chiba, Ehime, Fukui, Gunma, Hiroshima, Hokkaido, Kagawa, Kanagawa

2020-07-14

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Bunkyō City, Chiba, Chūōku, Fukuoka, Hamamatsu, Hirakata-shi, Hirosaki-shi, Isehara-shi

2020-07-13

Active, closed

Amplatzer Amulet LAAO vs. NOAC

NCT04226547Atrial Fibrillation, Stroke, Bleeding

DrugNOAC

Abbott Medical Devices

Not applicable

2,650

Toyohashi, Chiba, Kitakyushu, Tsukuba, Kamakura, Sendai, Kurashiki-shi, Meguro-ku

2020-07-07

Active, closed

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

NCT04446351Neoplasms

DrugsNelistotug·Belrestotug·Cobolimab·Dostarlimab

GlaxoSmithKline

Phase 1

107

Chiba, Tokyo

2020-06-25

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku

2020-04-16

Active, closed

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210Multiple Myeloma

DrugsBelantamab mafodotin·Dexamethasone

GlaxoSmithKline

Phase 3

325

Shibuya-Ku, Aichi, Chiba, Ehime, Fukushima, Gifu, Gunma, Hokkaido

2020-04-02

Active, closed

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856Urothelial Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Astellas Pharma Global Development, Inc.

Phase 3

886

Bunkyō City, Chiba, Fukuoka, Hirosaki, Kawasaki-shi, Kōtoku, Kyoto, Niigata

2020-03-30

Active, closed

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT04088396Systemic Juvenile Idiopathic Arthritis

DrugsBaricitinib·Tocilizumab

Eli Lilly and Company

Phase 3

Bunkyō, Chiba, Kagoshima, Sendai, Takatsuki, Yokohama

2020-02-12

Active, closed

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

NCT04161898Takayasu Arteritis (TAK)

DrugsUpadacitinib·Prednisolone

AbbVie

Phase 3

Chiba, Toon-shi, Maebashi, Sapporo, Tsukuba, Kita-gun, Kawasaki-shi, Yokohama

2020-02-04

Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198Myelofibrosis

DrugsMomelotinib·Ruxolitinib

Sumitomo Pharma America, Inc.

Phase 1/2

240

Aichi, Aomori, Chiba, Fukuoka, Hokkaido, Kamakura, Miyazaki, Okayama

2019-12-16

Active, closed

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 2

515

Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Kobe, Isehara-Shi, Kyoto

2019-11-13

Active, closed

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

NCT04145622Advanced Solid Tumor, Malignant Solid Tumor

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

247

Aichi, Chiba, Hokkaido, Hyōgo, Kagawa, Osaka, Ōsaka-sayama, Saitama

2019-11-03

Active, closed

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

DrugZipalertinib

Cullinan Therapeutics Inc.

Phase 1/2

284

Chiba, Niigata, Osaka, Shizuoka, Tokyo

2019-10-31

Active, closed

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348Eosinophilic Granulomatous Vasculitis

DrugsBenralizumab·Mepolizumab

AstraZeneca

Phase 3

140

Chiba, Kita-gun, Sagamihara-shi, Sendai, Shinjuku-ku

2019-10-29

Active, closed

SyncAV Post-Market Trial

NCT04100148Congestive Heart Failure

Abbott Medical Devices

Not applicable

1,686

Chiba, Nishinomiya, Kawasaki, Sagamihara

2019-10-03

Recruiting

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

NCT04288999Rectal Cancer Recurrent

National Cancer Center Hospital East

Phase 3

110

Chiba, Gifu, Hidaka, Hirakata, Hiroshima, Izumo, Kanazawa, Kashiwa

2019-10-01

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Bunkyō City, Chiba, Chikushino-shi, Ehime, Fujiidera-shi, Fukuoka, Fukuoka-ken, Fukushima

2019-09-26

Active, closed

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

DrugsBendamustine·Zanubrutinib·Rituximab

BeOne Medicines

Phase 3

510

Nagoya, Toyohashi, Chiba, Kurume, Hiroshima, Yokohama, Kumamoto, Kyoto

2019-08-20

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Hirosaki-shi, Chiba, Kashiwa-Shi, Matsuyama, Fukuoka, Kobe, Tsukuba, Kanazawa

2019-08-09

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsFluorouracil·Leucovorin·Ipilimumab·Irinotecan

Bristol-Myers Squibb

Phase 3

839

Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kawasaki

2019-08-05

Active, closed

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244Prostatic Neoplasms

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

2,517

Akita, Chiba, Chūōku, Hakodate, Hirosaki, Kanazawa, Kobe, Koshigaya

2019-06-11

Recruiting

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

NCT03773965Juvenile Idiopathic Arthritis

DrugBaricitinib

Eli Lilly and Company

Phase 3

190

Bunkyō, Chiba, Kagoshima, Kanazawa, Niigata, Saitama-shi, Sendai, Shinjuku-ku

2019-04-05

Active, closed

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455Early Alzheimer's Disease

DrugLecanemab

Eisai Inc.

Phase 3

1,906

Obu-shi, Chiba, Eiheiji-cho, Yoshida-gun, Fujioka-shi, Ōtake, Sapporo, Himeji-shi, Kobe

2019-03-27

Recruiting

Cardiac Sarcoidosis Randomized Trial

NCT03593759Cardiac Sarcoidosis, Sarcoidosis

DrugsPrednisolone·Methotrexate·Prednisone

Ottawa Heart Institute Research Corporation

Phase 3

160

Sapporo, Chiba, Fukui, Kawasaki, Nagoya, Osaka, Tokyo

2019-01-15

Active, closed

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114Relapsing Multiple Sclerosis

Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab

Novartis Pharmaceuticals

Phase 3

1,882

Tōon, Sapporo, Shiwa-Gun, Sendai, Kawagoe, Kodaira, Shinjuku-ku, Chiba

2018-12-28

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Nagoya, Kashiwa, Akashi, Kita-gun, Minato, Chiba, Fukuoka, Hiroshima

2018-12-17

Active, closed

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957Hepatocellular Carcinoma

DrugsAvastin·Durvalumab·Bevacizumab

AstraZeneca

Phase 3

724

Bunkyō City, Chiba, Chūōku, Fukuoka, Hiroshima, Kurume-shi, Musashino-shi, Nagoya

2018-11-30

Active, closed

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

507

Fukuoka, Akashi, Kawasaki, Yokohama, Suita, Utsunomiya, Chiba, Kashiwa

2018-11-28

Active, closed

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536Non-small Cell Lung Cancer

DrugTelisotuzumab vedotin

AbbVie

Phase 2

270

Nagoya, Hirosaki-shi, Chiba, Matsuyama, Fukuoka, Kurume-shi, Fukuyama, Hiroshima

2018-10-10

Active, closed

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

DrugsPonatinib·Imatinib·Cytarabine·Vincristine

Takeda

Phase 3

245

Chiba, Kashiwa, Fukushima, Sapporo, Isehara, Okayama

2018-10-04

Recruiting

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

NCT04174157Spinal Muscular Atrophy (SMA)

DrugZolgensma

Novartis Pharmaceuticals

Observational

700

Nagakute-shi, Toyoake-shi, Chiba, Kurume-shi, Gifu, Sapporo, Kita-gun, Yokohama

2018-09-25

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Nagakute, Nagoya, Toyoake, Hirosaki-shi, Abiko-shi, Chiba, Kashiwa-shi, Sakura-shi

2018-08-28

Active, closed

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

NCT03456076Carcinoma, Non-Small-Cell Lung

DrugsAlectinib·Vinorelbine·Pemetrexed·Gemcitabine

Hoffmann-La Roche

Phase 3

257

Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto

2018-08-16

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796Neoplasms

Celgene

Phase 2/3

1,541

Chiba, Sapporo, Tennoji-Ku, Shimotsuke, Chuo-ku, Minato-ku, Bunkyō City, Fukuoka

2018-07-19

Active, closed

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

NCT03505320Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin

DrugsFolinic acid·Zolbetuximab·Fluorouracil·Leucovorin

Astellas Pharma Global Development, Inc.

Phase 2

143

Chiba, Tokyo

2018-06-29

Active, closed

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411Crohn's Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab

Janssen Research & Development, LLC

Phase 2/3

1,409

Asahikawa, Bunkyō City, Chiba, Chikushino-shi, Fukuoka, Gifu, Hachiōji, Hamamatsu

2018-04-13

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Nagakute, Nagoya, Toyoake-shi, Abiko-shi, Chiba, Kashiwa-shi, Sakura-shi, Fukuoka

2018-04-09

Active, closed

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504Urothelial Cancer

DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

629

Chiba, Hirosaki, Kashiwa, Kita Gun, Kobe, Koshigaya, Matsuyama, Miyazaki

2018-03-23

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Bunkyoku, Chiba, Fukuoka, Hiroshima, Iizuka, Kanazawa, Kōtoku, Kumamoto

2017-10-11

Active, closed

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

NCT03252808Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV

DrugsTS-1·Abraxane·Nab-paclitaxel·Gemcitabine

Takara Bio Inc.

Phase 1

Nagoya, Chiba, Kashiwa, Yokohama, Osaka, Chūōku, Koto-Ku

2017-09-25

Active, closed

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997Breast Cancer

DrugAbemaciclib

Eli Lilly and Company

Phase 3

5,637

Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Ōta, Hiroshima, Sapporo

2017-07-12

Active, closed

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

NCT03036098Urothelial Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

1,314

Hirosaki, Chiba, Matsuyama, Fukuoka, Sapporo, Tsukuba, Morioka, Kita-Gun

2017-03-24

Active, closed

Japanese Idiopathic Interstitial Pneumonias Registry

NCT03041623Idiopathic Interstitial Pneumonia

North East Japan Study Group

Observational

867

Kiyosu, Nagoya, Seto, Toyoake, Hirosaki, Chiba, Kamogawa, Matsuyama

2016-12

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Aichi, Akita, Aomori, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo

2016-10-13

Active, closed

PALbociclib CoLlaborative Adjuvant Study

NCT02513394Breast Cancer

DrugPalbociclib

Alliance Foundation Trials, LLC.

Phase 3

5,796

Nagoya, Sapporo, Chiba, Kyoto, Osaka

2015-08

Active, closed

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

NCT02320435Solid Tumors

DrugsPerjeta·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

154

Chiba, Gifu, Saitama

2015-02-02

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 3

493

Nagoya, Chiba, Matsuyama, Sapporo, Nishinomiya, Yokohama, Niigata, Ōsaka-sayama

2014-11-06

Active, closed

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703Breast Neoplasms

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

669

Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Sapporo, Nishinomiya, Kawasaki

2014-07-22

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

1,837

Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa

2014-04-22

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742Fabry Disease

Genzyme, a Sanofi Company

Observational

9,000

Kobe, Nankoku, Chiba, Niigata, Osaka, Tokyo

2001-07-31

Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Genzyme, a Sanofi Company

Observational

12,000

Yonago, Chiba, Osaka, Tokyo

1991-04-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/chiba

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 331 of those studies with a site in Chiba.

How many clinical trials are recruiting in Chiba?

146 of the 331 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 3 have not yet opened recruitment, 174 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chiba), 331 studies
Phase	Studies	Recruiting	Share
Phase 3	205	88	61.9%
Phase 2	37	14	11.2%
Observational	25	12	7.6%
Phase 1	21	9	6.3%
Phase 1/2	16	9	4.8%
Phase 2/3	14	10	4.2%
Not applicable	12	3	3.6%
Phase 4	1	1	0.3%

Most active sponsors

Lead sponsors with the most studies (Chiba)
Lead sponsor	Studies	Recruiting
AstraZeneca	46	20
GlaxoSmithKline	26	11
Janssen Research & Development, LLC	21	13
Eli Lilly and Company	19	10
Hoffmann-La Roche	18	5
Novartis Pharmaceuticals	16	6
Bristol-Myers Squibb	12	6
Pfizer	12	7
AbbVie	11	1
Gilead Sciences	8	2

→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.